[1] Yoshida
K, Yokoi A, Kato T, et al. The clinical impact of intra- and extracellular
miRNAs in ovarian cancer [J]. Cancer Sci, 2020, 111(10): 3435-3444.
DOI:10.1111/cas.14599.
[2] 陆林, 杨丽敏, 徐成娟. 贝伐单抗联合去甲基斑蝥素治疗卵巢癌患者的效果及对患者PAI-1表达的影响 [J]. 国际医药卫生导报, 2020, 26(22): 3459-3461.
DOI:10.3760/cma.j.issn.1007-1245.2020.22.028.
[3] Aziz NB, Mahmudunnabi RG, Umer M, et al.
MicroRNAs in ovarian cancer and recent advances in the development of
microRNA-based biosensors [J]. Analyst, 2020, 145(6): 2038-2057.
DOI:10.1039/C9AN02263E.
[4] Ma LL, Liang L, Zhou D, et al. Tumor
suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting
ACSL4 [J]. Neoplasma, 2021, 68(1): 165-173. DOI:10.4149/neo_2020_200707N705.
[5] Liu X, Meng Z, Xing Y, et al. MiR-127
inhibits ovarian cancer migration and invasion by up-regulating ITGA6 [J].
Minerva Med, 2021, 112(2): 309-310. DOI:10.23736/S0026-4806.19.06237-2.
[6] Yang L, Ma HL. MiRNA-584 suppresses the
progression of ovarian cancer by negatively regulating LPIN1 [J]. Eur Rev Med
Pharmacol Sci, 2020, 24(3): 1062-1071. DOI:10.26355/eurrev_202002_20156.
[7] Kuang Y, Xu H, Lu F, et al. Inhibition
of microRNA let-7b expression by KDM2B promotes cancer progression by targeting
EZH2 in ovarian cancer [J]. Cancer Sci, 2021, 112(1): 231-242.
DOI:10.1111/cas.14708.
[8] Wei L, He Y, Bi S, et al. miRNA‑199b‑3p
suppresses growth and progression of ovarian cancer via the CHK1/E‑cadherin/EMT
signaling pathway by targeting ZEB1 [J]. Oncol Rep, 2020, 45(2): 569-581.
DOI:10.3892/or.2020.7895.
[9] Cao J, Wang H, Liu G, et al. LBX2-AS1
promotes ovarian cancer progression by facilitating E2F2 gene expression via
miR-455-5p and miR-491-5p sponging [J]. J Cell Mol Med, 2021, 25(2): 1178-1189.
DOI:10.21203/rs.3.rs-34251/v1.
[10] Yao CJ, Chen CY, Qiu XY, et al.
MicroRNA-378a-3p contributes to ovarian cancer progression through
downregulating PDIA4 [J]. Immun Inflamm Dis, 2021, 9(1): 108-119.
DOI:10.1002/iid3.350.
[11] Wang Z, Han Y, Xing X, et al. MiRNA-98
inhibits ovarian carcinoma cell proliferation, migration and invasion via
targeting SALL4 [J]. Minerva Med, 2021, 112(1): 154-155.
DOI:10.23736/S0026-4806.19.06179-2.
[12] Zhang C, Huang D, Liu A, et al.
Genome-wide screening and cohorts validation identifying novel lncRNAs as
prognostic biomarkers for clear cell renal cell carcinoma [J]. J Cell Biochem,
2020, 121(3): 2559-2570. DOI:10.1002/jcb.29478.
[13] Zuo Y, Zheng W, Liu J, et al.
MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer
cells [J]. Neoplasma, 2020, 67(1): 93-101. DOI:10.4149/neo_2019_190202N106.
[14] Zhou P, Xiong T, Yao L, et al.
MicroRNA-665 promotes the proliferation of ovarian cancer cells by targeting
SRCIN1 [J]. Exp Ther Med, 2020, 19(2): 1112-1120. DOI:10.3892/etm.2019.8293.
[15] Jin Y, Wei J, Xu S, et al. miR‑210‑3p
regulates cell growth and affects cisplatin sensitivity in human ovarian cancer
cells via targeting E2F3 [J]. Mol Med Rep, 2019, 19(6): 4946-4954.
DOI:10.3892/mmr.2019.10129.
[16] Li Y, Lin Q, Chang S, et al. Vitamin D3
mediates miR-15a-5p inhibition of liver cancer cell proliferation via targeting
E2F3 [J]. Oncol Lett, 2020, 20(1): 292-298. DOI:10.3892/ol.2020.11572. |